Clinical efficacy of the antiprogesterone XXXX in the treatment of @entity46 and uterine fibroids.

@entity1 @entity251 @entity2931 @entity2371 @entity530 @entity134 @entity46 @entity158 @entity3927 @entity1868 @entity2671
To evaluate the long-term effects of treatment with @entity3927 and to test its efficacy in @entity46 , a 3-month trial was conducted to evaluate the effects of daily administration (100 mg/day or approximately 2 mg/kg/day) on the functional activity of the reproductive axis, as well as implants, in @entity1 with symptomatic @entity530 . All @entity1 became amenorrhoeic and acyclic. However, ovarian suppression was incomplete. In 24 h sampling studies, mean luteinizing hormone (LH) and LH pulse amplitude were increased without a change in LH pulse frequency. Additionally, an antiglucocorticoid effect was demonstrated. Treatment resulted in improvement in @entity2371 in all subjects without significant changes in the extent of disease as evaluated by laparoscopy. We also attempted to reduce the growth of uterine fibroids by using 50 mg/day of @entity3927 for 3 months in 10 @entity1 . @entity1868 size decreased approximately 22% at 4 weeks, 39% at 8 weeks and 49% at 12 weeks. Serum concentrations of LH, @entity2671 and @entity251 increased in the first 3 weeks of treatment and then returned to baseline. In conclusion, daily administration of @entity3927 resulted in ovarian inhibition and menstrual acyclicity and in an improvement in the @entity158 associated with @entity530 and decreased the size of uterine fibroids. This ovarian inhibition was achieved without @entity2931 deprivation and may provide a novel long-term approach to the treatment of ovarian @entity134 -dependent disease processes.
